Allergy and Asthma Proceedings, Journal Year: 2024, Volume and Issue: 46(1), P. 11 - 18

Published: Dec. 31, 2024

Background: Patients with mast cell activation syndrome (MCAS) can be refractory to standard antimediator therapy. Alternative treatment options reduce disease burden and improve quality of life are needed. Objective: To compile the evidence that supports use omalizumab for patients MCAS. Methods: Through a systematic review PubMed database, we compiled analyzed characteristics MCAS, unresponsive histamine 1 receptor antihistamines plus another agent (refractory MCAS), who were treated omalizumab. We categorized clinical response as no, partial, or complete response. Results: identified nine studies described total 28 (median age, 48 years; males, 54%) Twenty-one (75%) had nonclonal seven (25%) clonal The dose ranged from 150 mg every 4 weeks 300 3 weeks, most common being 2 weeks. Most partial (61%), five achieved Omalizumab was successful in ameliorating anaphylaxis allowed discontinuation systemic glucocorticoids two three patients. pattern not influenced by sex clonality, but reported more commonly among receivers higher (≥300 mg/month). No major adverse events reported. Conclusion: majority MCAS literature reduction mediator-related symptoms addition

Language: Английский